# Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

> **NCT00099216** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 708 (actual)

## Conditions studied

- Vascular Dementia

## Interventions

- **DRUG:** Rivastigmine

## Key facts

- **NCT ID:** NCT00099216
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 708 (ACTUAL)
- **Last updated:** 2011-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099216, "Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00099216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*